NewAmsterdam Pharma Co N.V. financial data

Symbol
NAMS, NAMSW on Nasdaq
Location
Gooimeer 2 35, Narrden, Netherlands
State of incorporation
Netherlands
Fiscal year end
December 31
Former names
NewAmsterdam Pharma Co B.V. (to 11/22/2022)
Latest financial report
10-Q - Q1 2024 - May 8, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90 M shares
Common Stock, Shares, Outstanding 89.7 M shares
Entity Public Float 577 M USD
Common Stock, Value, Issued 11.1 M USD
Weighted Average Number of Shares Outstanding, Basic 88.4 M shares +8.26%
Weighted Average Number of Shares Outstanding, Diluted 88.4 M shares +8.26%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.4 M USD -83.8%
Research and Development Expense 42.4 M USD +4.97%
Operating Income (Loss) -55.5 M USD -39.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -93.8 M USD -123%
Net Income (Loss) Attributable to Parent -93.8 M USD -123%
Earnings Per Share, Basic -1.06 USD/shares -108%
Earnings Per Share, Diluted -1.06 USD/shares -108%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 488 M USD
Property, Plant and Equipment, Net 101 K USD
Operating Lease, Right-of-Use Asset 38 K USD
Assets 488 M USD
Accounts Payable, Current 8.54 M USD
Liabilities, Current 59.7 M USD
Operating Lease, Liability, Noncurrent 60 K USD
Liabilities 76.7 M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.42 M USD
Retained Earnings (Accumulated Deficit) -411 M USD
Stockholders' Equity Attributable to Parent 412 M USD +3.36%
Liabilities and Equity 488 M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -54.6 M USD -71.4%
Net Cash Provided by (Used in) Financing Activities 198 M USD +8185%
Net Cash Provided by (Used in) Investing Activities -385 K USD -5400%
Common Stock, Shares Authorized 400 M shares
Common Stock, Shares, Issued 89.7 M shares
Common Stock, Par or Stated Value Per Share 0.12 EUR/shares
Deferred Tax Assets, Valuation Allowance 130 M USD +59.6%
Deferred Tax Assets, Gross 130 M USD +59.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -93.8 M USD -123%
Operating Lease, Liability, Current 43 K USD
Deferred Tax Assets, Operating Loss Carryforwards 75.7 M USD +31%
Unrecognized Tax Benefits 0 USD
Depreciation, Depletion and Amortization 15 K USD +66.7%
Deferred Tax Assets, Net of Valuation Allowance 12 K USD -55.6%
Share-based Payment Arrangement, Expense 7.92 M USD +3.97%